Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD

Yvette RBM van Gestel¹
Sanne E Hoeks¹
Don D Sin²
Henk Stam³
Frans W Mertens³
Jeroen J Bax⁴
Ron T van Domburg⁵
Don Poldermans⁶
¹Department of Anesthesiology, Erasmus Medical Center, Rotterdam, The Netherlands; ²Department of Medicine, University of British Columbia and The James Hogg ICAPTURE Center, St. Paul’s Hospital, Vancouver, Canada; ³Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands; ⁴Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; ⁵Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands; ⁶Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands

Background: Beta-blockers are frequently withheld in patients with cardiovascular disease who also have chronic obstructive pulmonary disease (COPD) because of concerns that they might provoke bronchospasm and cause deterioration in health status. Although beta1-selective beta-blockers are associated with reduced mortality in COPD patients, their effects on health status are unknown. The aim of this study was to investigate the relationship between beta-blockers and health-related quality of life (HRQOL) in patients with peripheral arterial disease and COPD.

Methods: Of the original cohort of 3371 vascular surgery patients, 1310 had COPD of whom 469 survived during long-term follow-up. These COPD patients were sent the Short Form-36 (SF-36) health-related quality of life questionnaire, which was completed and returned by 326 (70%) patients.

Results: No significant differences in any of the SF-36 domains were observed between COPD patients who did and did not use beta-blockers (p > 0.05 for all). Furthermore, beta-blockers were not associated with any impairment in HRQOL among patients with COPD.

Conclusion: Beta-blockers had no material impact on the HRQOL of patients with peripheral arterial disease who also had COPD. This suggests that beta-blockers can, in most circumstances, be administered to patients with COPD without impairment in HRQOL.

Keywords: beta-blockers, chronic obstructive pulmonary disease, vascular surgery, health-related quality of life

Introduction

Patients with chronic obstructive pulmonary disease (COPD) often have or develop co-existing cardiovascular diseases including congestive heart failure, ischemic heart disease and hypertension.¹ Beta-blockers are indicated in most of these conditions, as they improve heart function, symptoms and survival.²,³ However, there is under-utilization of beta-blockers in cardiovascular patients with COPD because of concerns that these drugs may induce bronchoconstriction and worsen symptoms.⁴ Although the data are mixed, the total evidence suggests that beta1-selective beta-blockers (at least in the short term) do not worsen pulmonary function⁵–¹⁰ and are associated with reduced mortality in patients with cardiovascular disease who have COPD.¹¹–¹³ The long-term effects on health status and health-related quality of life (HRQOL) of beta-blockers in COPD are unknown. On the one hand, beta-blockers may improve HRQOL because of their beneficial effects on cardiac performance; on the other hand, beta-blockers may cause impaired physical, social and emotional functioning owing to their side effects and/or by causing worsening of lung function. The latter may partly explain
the sub-optimal prescription rate of these drugs for patients with COPD. We thus sought to determine the relationship between beta-blockers and HRQOL of patients with peripheral arterial disease, who also had COPD.

**Methods**

**Patients**

The study is based on a subgroup of the original cohort of vascular surgery patients, who have been described previously. Briefly, a detailed cardiac history, in addition to clinical and demographic characteristics, were obtained in all patients undergoing a peripheral vascular operative procedure prior to their surgery. Their survival status was ascertained at long-term follow-up (up to 10 years) using the municipal civil registry. HRQOL of patients was determined at follow-up using a self-administered questionnaire that was mailed to all eligible subjects (see below). In this mailing, we also obtained information regarding the use of beta-blockers using a short questionnaire.

**COPD**

The diagnosis of COPD was based on spirometric evidence for fixed airflow obstruction as assessed by a post-bronchodilator forced expiratory volume in one second (FEV$_1$) to forced vital capacity (FVC) ratio of less than 0.70 and FEV$_1$ of <80% of predicted, which was obtained at baseline prior to their original vascular surgery. Patients who did not undergo spirometry were categorized as not having COPD if they did not complain of cough, dyspnea or sputum production, were not taking any pulmonary medication (bronchodilators or corticosteroids) and demonstrated normal arterial blood gases on room air defined by arterial carbon dioxide tension (paCO$_2$) < 6.4 kPa and oxygen tension (paO$_2$) > 10.0 kPa. Patients without spirometry who met any one of these criteria were classified as having COPD.

**Health-related quality of life**

For the assessment of HRQOL, the Dutch version of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) was used. SF-36 is a widely used generic questionnaire to measure patients’ health status and has been used previously in patients with COPD. The questionnaire contains 36 items covering 8 domains: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH). The domains scores range from 0 to 100, with higher scores indicating better HRQOL.

**Statistical analysis**

The primary exposure variable was the use of beta-blockers at baseline and the primary endpoint of the present study was HRQOL at follow-up. The baseline categorical variables of the patients who did and did not use a beta-blocker were compared using a chi-square test for dichotomous variables and a Student’s t-test for continuous variables. Dichotomous variables are presented as percentages, while continuous variables are presented as mean ± standard deviation (SD). The domains of the SF-36 were converted into tertiles for parsimony and subsequently dichotomized, with the lowest tertile indicating worst health status and the highest two tertiles representing best health status. Univariate and multivariate logistic regression analyses were used to determine the association between beta-blocker use and health status. In the multivariate analysis, adjustments were made for all baseline characteristics that might reasonably affect HRQOL including age, gender, diabetes mellitus, hypertension, hypercholesterolemia, renal dysfunction, current smoking, obesity, type of surgery (abdominal aortic surgery [AAA], carotid endarterectomy [CEA], or lower limb arterial reconstruction procedures [LLR]), year of surgery, previous ischemic heart disease (myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention or angina pectoris), heart failure, cerebrovascular event (CVA) or transient ischemic attack (TIA), statins, aspirin, corticosteroids and bronchodilators. To correct for the differential follow-up, adjustments were made for the number of follow-up years. Additionally, a propensity score was added as a covariate to the model to adjust for the likelihood of receiving beta-blockers. This propensity model contained all variables which were included in the logistic regression analysis, except for the number of follow-up years. Odds ratios (OR) are presented as risk estimates with 95% confidence intervals (CI). For all tests, a 2-sided p-value of <0.05 was considered significant. All tests were performed using SPSS 15.0 for Windows.

**Results**

**Patients**

In total, 1310 (39%) of the original 3371 patients had COPD. Of these patients, two had moved abroad, 28 were lost to follow-up and 469 (36%) survived during the follow-up period. The median follow-up time was 6.4 years with an interquartile range of 2.9 to 9.3 years. All 469 patients were sent the SF-36 questionnaire at follow-up, which was completed and returned by 326 (70%) patients. An overview of the patient inclusion for this study is presented in Figure 1.
Clinical baseline characteristics are presented in Table 1. Of the 326 patients with peripheral arterial disease and COPD, 59% (n = 191) received beta-blockers. The mean age was 66 ± 10 years and 80% (n = 262) were men. Patients on beta-blockers were older and were more likely to have had a previous myocardial infarction, coronary revascularization, angina pectoris, diabetes mellitus, renal dysfunction and hypercholesterolemia compared with those who were not on beta-blockers (all p-values < 0.05). These patients also received more often other medications like statins, aspirin and corticosteroids (p < 0.05). Only two differences were found in baseline characteristics between the COPD patients who filled out the questionnaire and those who did not respond. The non-responding patients were more likely to be women and had more frequent history of renal dysfunction (p < 0.05).

Beta-blockers and COPD
Of the 326 responding COPD patients, 191 (59%) patients used beta-blockers at baseline. Of these, 174 (91%) received beta-blocker therapy baseline (n = 191, 59%). Of these, 31 stopped beta-blocker and 72 started beta-blocker. Of the remaining patients, 135 (41%) did not use beta-blockers at baseline (n = 135, 41%). Of these, 30 (22%) were lost to follow-up/emigrated. Of the responding patients, 326 (70%) filled out the questionnaire. Of these, 232 (71%) continued using beta-blockers and 94 (29%) did not use beta-blockers at follow-up.
van Gestel et al

**Table 1** Baseline characteristics of the study patients

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 326)</th>
<th>Beta-blockers* (n = 191)</th>
<th>No beta-blockers (n = 135)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age years (mean (SD))</td>
<td>66 (10)</td>
<td>68 (9)</td>
<td>64 (11)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male gender</td>
<td>80%</td>
<td>81%</td>
<td>79%</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>Type of surgery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AAA</td>
<td>50%</td>
<td>53%</td>
<td>44%</td>
<td>0.28</td>
</tr>
<tr>
<td>CEA</td>
<td>21%</td>
<td>20%</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>LLR</td>
<td>29%</td>
<td>27%</td>
<td>33%</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular history</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>26%</td>
<td>33%</td>
<td>16%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Coronary revascularization(^{b})</td>
<td>23%</td>
<td>28%</td>
<td>15%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Heart failure</td>
<td>5%</td>
<td>4%</td>
<td>5%</td>
<td>0.67</td>
</tr>
<tr>
<td>Angina pectoris</td>
<td>20%</td>
<td>29%</td>
<td>8%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Stroke or TIA</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Clinical characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD</td>
<td></td>
<td></td>
<td></td>
<td>0.43</td>
</tr>
<tr>
<td>Mild COPD</td>
<td>54%</td>
<td>54%</td>
<td>53%</td>
<td></td>
</tr>
<tr>
<td>Moderate COPD</td>
<td>37%</td>
<td>36%</td>
<td>40%</td>
<td></td>
</tr>
<tr>
<td>Severe COPD</td>
<td>9%</td>
<td>11%</td>
<td>7%</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>43%</td>
<td>46%</td>
<td>39%</td>
<td>0.26</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>14%</td>
<td>20%</td>
<td>4%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>23%</td>
<td>28%</td>
<td>16%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>19%</td>
<td>23%</td>
<td>12%</td>
<td>0.01</td>
</tr>
<tr>
<td>Body mass index (mean (SD))</td>
<td>26 (4)</td>
<td>26 (4)</td>
<td>26 (4)</td>
<td>0.81</td>
</tr>
<tr>
<td>Current smoking status</td>
<td>31%</td>
<td>32%</td>
<td>29%</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Medication</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statins</td>
<td>44%</td>
<td>58%</td>
<td>23%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aspirin</td>
<td>49%</td>
<td>56%</td>
<td>39%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>10%</td>
<td>11%</td>
<td>10%</td>
<td>0.98</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>15%</td>
<td>19%</td>
<td>10%</td>
<td>0.04</td>
</tr>
</tbody>
</table>

\(^{a}\)Use at baseline.
\(^{b}\)Coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).

**Abbreviations:** AAA, abdominal aortic surgery; CEA, carotid endarterectomy; LLR, lower limb arterial reconstruction; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease.

A beta1-selective beta-blocker (ie, bisoprolol, metoprolol or atenolol). Of the 191 patients who had received beta-blockers at baseline, 31 (16%) had discontinued its use (by self-report) at follow-up. All of these patients were probed to ascertain the cause for the discontinuation; in no case was worsening of pulmonary symptoms noted. The distribution of beta-blocker discontinuation between those with and without COPD was similar (of the patients who had discontinued, 54% did not have COPD and 46% had COPD). At baseline 135 COPD patients were not treated with beta-blockers, however at follow-up, 72 (53%) of these patients had initiated beta-blocker therapy. In total, 232 (71%) patients were using beta-blockers by the end of follow-up. Of these, 204 (88%) used beta1-selective beta-blockers (Figure 1).

**Health-related quality of life**

The mean scores on the SF-36 domains according to beta-blocker use are presented in Figure 2a. There were no significant differences in HRQOL scores between those who were and were not taking beta-blockers (p > 0.05 for all). Multivariate analyses also showed no significant associations between beta-blockers and the individual domains of the SF-36 in patients with COPD: (PF: OR 1.36; 95% CI 0.72–2.61, RP: OR 1.55; 95% CI 0.78–3.06, BP: OR 1.00; 95% CI 0.52–1.94, GH: OR 1.27; 95% CI 0.67–2.41, VT: OR 1.29; 95% CI 0.68–2.44,
Beta-blockers and HRQL in PAH and COPD patients

Discussion

In the present study we investigated the relationship between beta-blockers and HRQL in patients with peripheral arterial disease and COPD. Our findings indicate that beta-blocker therapy does not impair HRQL in this patient population.

These data are similar to a recent review and meta-analysis in patients with chronic heart failure, which demonstrated that beta-blocker therapy did not impair HRQL.22 We extend these findings by demonstrating a similar relationship in COPD patients. The results of our study are also consistent with those reported by Mascarenhas and colleagues23 who in a cohort of patients with heart failure and COPD, found a low withdrawal rate of beta-blockers because of adverse effects among those who used these drugs.

Although clinicians are reluctant to prescribe beta-blockers to COPD patients for fear of provoking bronchospasm and exacerbating lung dysfunction, there is compelling evidence to indicate that the benefits (related to cardiovascular morbidity and mortality) are likely to outweigh the potential risk of adverse events in patients with COPD, especially when beta1-selective beta-blockers are used.11–13,24 Previous studies suggest that beta1-selective beta-blockers can be given safely to patients with COPD and do not worsen pulmonary function at least in the short-term when used cautiously.5–10

We have also observed previously that intensified doses of beta-blockers were superior to low-dose therapy in reducing mortality in patients with COPD, which suggests that although it is reasonable to initiate beta-blockers at a low dose, if possible, the dose should be titrated upwards judiciously and slowly to the therapeutic doses in these patients.11

Besides survival and adverse effect, it is also important to study the impact of medical treatment on patients’ perspective of their health status. To date, HRQL is often used as a secondary endpoint. However, as the focus of COPD management is to improve HRQL, it is important that HRQL is not adversely affected by medical therapy that potentially prolongs survival, eg, by the treatment with beta-blockers. Moreover, knowledge of the patients’ perception of the effect of therapy is essential for the physicians’ treatment decisions. Importantly, the results of our study indicate that beta-blocker therapy does not impair patients’ health status and could be used in patients with cardiovascular disease and COPD.

The study has some limitations. First, our study was not a randomized controlled trial. As such, although adjustments were made for known covariates, there is the possibility of confounding by unmeasured variables. In addition, beta-blockers were not randomly assigned and therefore subject to confounding by indication. However, propensity analysis was performed to adjust as much as possible for this type of bias.25 We did

SF: OR 1.59; 95% CI 0.87–2.92, RE: OR 1.00; 95% CI 0.50–1.97, MH: OR 1.15; 95% CI 0.62–2.14) (Figure 3a).

We also evaluated the impact of beta-blocker use at follow-up on HRQOL. Again, there were no significant differences in mean HRQOL scores between patients who were and were not treated with beta-blockers (Figure 2b). Beta-blocker therapy at follow-up was not associated with impaired health status (PF: OR 1.27; 95% CI 0.72–2.27, RP: OR 1.66; 95% CI 0.92–2.98, BP: OR 0.96; 95% CI 0.55–1.69, GH: OR 1.50; 95% CI 0.84–2.66, VT: OR 1.22; 95% CI 0.69–2.14, SF: OR 1.34; 95% CI 0.78–2.29, RE: OR 1.27; 95% CI 0.70–2.30, MH: OR 1.57; 95% CI 0.89–2.75) (Figure 3b).

Discussion

In the present study we investigated the relationship between beta-blockers and HRQL in patients with peripheral arterial disease and COPD. Our findings indicate that beta-blocker therapy does not impair HRQL in this patient population.

These data are similar to a recent review and meta-analysis in patients with chronic heart failure, which demonstrated that beta-blocker therapy did not impair HRQL.22 We extend these findings by demonstrating a similar relationship in COPD patients. The results of our study are also consistent with those reported by Mascarenhas and colleagues23 who in a cohort of patients with heart failure and COPD, found a low withdrawal rate of beta-blockers because of adverse effects among those who used these drugs.

Although clinicians are reluctant to prescribe beta-blockers to COPD patients for fear of provoking bronchospasm and exacerbating lung dysfunction, there is compelling evidence to indicate that the benefits (related to cardiovascular morbidity and mortality) are likely to outweigh the potential risk of adverse events in patients with COPD, especially when beta1-selective beta-blockers are used.11–13,24 Previous studies suggest that beta1-selective beta-blockers can be given safely to patients with COPD and do not worsen pulmonary function at least in the short-term when used cautiously.5–10

We have also observed previously that intensified doses of beta-blockers were superior to low-dose therapy in reducing mortality in patients with COPD, which suggests that although it is reasonable to initiate beta-blockers at a low dose, if possible, the dose should be titrated upwards judiciously and slowly to the therapeutic doses in these patients.11

Besides survival and adverse effect, it is also important to study the impact of medical treatment on patients’ perspective of their health status. To date, HRQL is often used as a secondary endpoint. However, as the focus of COPD management is to improve HRQL, it is important that HRQL is not adversely affected by medical therapy that potentially prolongs survival, eg, by the treatment with beta-blockers. Moreover, knowledge of the patients’ perception of the effect of therapy is essential for the physicians’ treatment decisions. Importantly, the results of our study indicate that beta-blocker therapy does not impair patients’ health status and could be used in patients with cardiovascular disease and COPD.

The study has some limitations. First, our study was not a randomized controlled trial. As such, although adjustments were made for known covariates, there is the possibility of confounding by unmeasured variables. In addition, beta-blockers were not randomly assigned and therefore subject to confounding by indication. However, propensity analysis was performed to adjust as much as possible for this type of bias.25 We did
not have accurate information on the duration of beta-blocker exposure and non-exposure. A more detailed analysis of the relationship between the duration of beta-blocker exposure (or non-exposure) at follow-up and HRQOL was therefore not possible (eg, a time-dependent covariate analysis). For these and other reasons, a randomized controlled trial is needed to validate these early findings. Furthermore, during follow-up, a number of patients stopped using beta-blockers. It was reassuring that patients did not report worsening of their lung condition or respiratory symptoms for the discontinuation. Nevertheless, a more detailed assessment of long-term pulmonary on and off beta-blockers, using patient-based symptoms questionnaire and lung function testing, would be helpful to better understand why certain patients with COPD discontinue beta-blocker therapy during follow-up.

In sum, although beta-blockers are often indicated in patients with cardiovascular disease, clinicians are reluctant to prescribe these drugs to patients with co-existing COPD for fear of inducing bronchospasm and worsening their health status. The findings of the present study suggest that general health status is not materially affected by these drugs. In view of their potential life-preserving effects in patients with cardiovascular disease, these results suggest that beta-blockers can in most circumstances be judiciously administered to patients with COPD without impairing their HRQOL.

**Acknowledgments**

YRBV van Gestel and SE Hoeks are supported by an unrestricted research grant from “Lijf & Leven” Foundation, Rotterdam, The Netherlands.

**Conflict of interest**

The authors disclose no conflicts of interest.

**References**